Phytosphingosine

Phytosphingosine

SCHEMBL833646

CCCCCCCCCCCCCCC(O)C(O)C(N)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.78
SPHK1 Q9NYA1 4/20 0.78
LMNA P02545 4/20 0.78
MAPT P10636 4/20 0.78
GMNN O75496 3/20 0.78
POLB P06746 3/20 0.78
BLM P54132 3/20 0.78
CETP P11597 3/20 0.78
UBE2N P61088 3/20 0.78
THPO P40225 2/20 0.78
TP53 P04637 2/20 0.78
CYP1A2 P05177 2/20 0.78
MTOR P42345 1/20 0.78
KDM4E B2RXH2 1/20 0.78
CYP3A4 P08684 1/20 0.78
HTT P42858 1/20 0.78
CSNK1E P49674 1/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
GLA P06280 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7171764 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL13780782 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
Phytosphingosine SCHEMBL5490039 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
Phytosphingosine SCHEMBL13146498 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL12279953 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
Phytosphingosine SCHEMBL12563454 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
Phytosphingosine SCHEMBL14415162 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
Phytosphingosine SCHEMBL14565602 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
Phytosphingosine SCHEMBL21484046 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL29822750 1.00 CYP2D6 (0.78) CYP2D6SPHK1LMNAMAPTGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116535331-A Ceramide derived from olive oil and application thereof 上海中翊日化有限公司 2023-08-04 CN claimed
CN-110117355-B Polyester resin with excellent neutral salt spray resistance for TG IC powder coating and preparation method thereof 黄山嘉恒科技有限公司 2021-06-15 CN claimed
CN-112201344-A Application of salivary metabolism marker in early diagnosis of oral lichen planus 郑州大学第一附属医院 2021-01-08 CN claimed
CN-110078635-A The synthesis and its application in Cer NP preparation that dewatering mechanism promotes amide 上海克琴科技有限公司 2019-08-02 CN claimed
US-20020006420-A1 USE OF A 2-AMINO-ALKANE POLYOL AS AGENT FOR TREATING SKIN AGEING SIGNS PHILIPPE MICHEL (FR) 2002-01-17 US claimed
US-6184252-B1 2-amino-1,3-alkanediol compositions for inducing/stimulating hair growth and/or retarding hair loss SOCIETE L'OREAL S.A. (FR) 2001-02-06 US claimed
EP-1001739-A1 USE OF A 2-AMINO-ALKANE POLYOL AS AGENT FOR TREATING SKIN AGEING SIGNS L'OREAL (FR) 2000-05-24 EP claimed
WO-1999007337-A1 USE OF A 2-AMINO-ALKANE POLYOL AS AGENT FOR TREATING SKIN AGEING SIGNS L'OREAL (FR) 1999-02-18 WO claimed
EP-0790053-B1 Use of 2-amino-alkane-1,3-diol to reduce hairloss and/or to induce and stimulate hairgrowth OREAL (FR) 1998-10-07 EP claimed
EP-0790053-A1 Use of 2-amino-alkane-1,3-diol to reduce hairloss and/or to induce and stimulate hairgrowth L'OREAL (FR) 1997-08-20 EP claimed
EP-4737504-A2 CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF Xiamen Sinopeg Biotech Co., Ltd. (CN) 2026-05-06 EP disclosed
EP-4276090-B1 CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF XIAMEN SINOPEG BIOTECH CO LTD (CN) 2026-04-29 EP disclosed
EP-4321504-B1 PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF XIAMEN SINOPEG BIOTECH CO LTD (CN) 2026-02-18 EP disclosed
US-20250339483-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF AGS THERAPEUTICS SAS (FR) 2025-11-06 US disclosed
EP-4624449-A1 VEGETABLE OIL CERAMIDES, SYNTHESIS METHOD THEREFOR, AND USE THEREOF Shenzhen Dikeman Biotechnology Co., Ltd. (CN) 2025-10-01 EP disclosed
EP-0736522-B1 Ceramide compounds, process for their preparation and their use in cosmetics or dermatology OREAL (FR) 1997-12-29 EP disclosed
EP-0790053-A1 Use of 2-amino-alkane-1,3-diol to reduce hairloss and/or to induce and stimulate hairgrowth L'OREAL (FR) 1997-08-20 EP disclosed
EP-0768299-B1 Process for the preparation of 2-amino-1,3,4-triol-alkanes OREAL (FR) 1997-08-06 EP disclosed
EP-0768299-A1 Process for the preparation of 2-amino-1,3,4-triol-alkanes L'OREAL (FR) 1997-04-16 EP disclosed
EP-0736522-A1 Ceramide compounds, process for their preparation and their use in cosmetics or dermatology L'OREAL (FR) 1996-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339483-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF NLN, DCX, CNTN1 CYP2D6 4280/4885SPHK1 1390/4885LMNA 861/4885
US-20020006420-A1 USE OF A 2-AMINO-ALKANE POLYOL AS AGENT FOR TREATING SKIN AGEING SIGNS CUTA, GLA, AGER CYP2D6 4135/4885SPHK1 2110/4885LMNA 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.